GlassScriptPhysician profile
Monali Shah
NPI 1336569292
$6,315.17
in general payments reported to CMS, 2019-2025
25 companies · $1,001 in 2025
The $1,001 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,139 · 2020: $223 · 2021: $793 · 2022: $1,105 · 2023: $923 · 2024: $1,131 · 2025: $1,001.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,055.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,055.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $1,139.41 | 2019 | |
| Impulse Dynamics (USA) INC. | $876.96 | 2021-2023 | Optimizer |
| Heartflow, INC. | $611.30 | 2023-2025 | Ffrct |
| Novartis Pharmaceuticals Corporation | $579.07 | 2021-2025 | |
| Abbott Laboratories | $476.31 | 2020-2024 | Thoratec Heartmate 3 Lvas Implant Kit |
| Amgen INC. | $436.57 | 2021-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $296.89 | 2023-2025 | Ekosonic, Watchman Access System |
| Pfizer INC. | $290.26 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $213.08 | 2021-2024 | Xarelto |
| Novo Nordisk INC | $194.27 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $182.12 | 2021-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $179.71 | 2021-2025 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $146.70 | 2021-2022 | |
| Abbvie INC. | $121.03 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $113.77 | 2020-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $107.05 | 2021-2023 | Verquvo, Steglatro |
| Daiichi Sankyo INC. | $74.34 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $70.64 | 2024-2025 | Eliquis, Camzyos |
| Biosense Webster, INC. | $43.43 | 2021 | |
| Atricure, INC. | $43.38 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $39.41 | 2021-2023 | |
| Regeneron Healthcare Solutions, INC. | $33.63 | 2024 | Evkeeza |
| Medtronic, INC. | $16.35 | 2021 | |
| Arineta, INC | $15.80 | 2024 | Spotlight |
| Gilead Sciences, INC. | $13.69 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monali Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.